What we are seeing in the market.
Operator analysis of health markets in Europe, the US, and MENA: four monthly Vital Signs editions, the PROGNOSIS flagship, perspectives, and the reference work behind them.
Operator analysis of health markets in Europe, the US, and MENA: four monthly Vital Signs editions, the PROGNOSIS flagship, perspectives, and the reference work behind them.
Vital Signs · MedTech
A device can wait about two years between its first approval and its second, and the lead piece sets out what stretched the longest waits. This month's deals show what buyers paid for medtech companies, from $240 million to $2.1 billion, and what Stryker's $400 million in CMR Surgical buys it.
27 October 2026
Perspective · AI Drug DiscoveryThree AI drug discovery companies at the HealthVC Summit each named a different missing experiment. What AI has already changed in drug R&D, what it has not, and where the capital is going.
Vital Signs · AI Drug DiscoveryAI drug discovery, September 2026: the AIntibody benchmark tested protein design methods blind, and ICH M15 now asks six questions of any model.